Founded in 2003, MSN Laboratories is one of the fastest-growing pharmaceutical manufacturers of APIs and finished dosages in India, operating nine API facilities, five finished dosage facilities and an integrated R&D center in Hyderabad, all accredited by the US FDA, EU-GMP, WHO Geneva, PIC/S, ANVISA, INVIMA and other global regulatory bodies. With a product portfolio spanning 35 major therapies including oncology, MSN reaches millions of people across 65 countries in North America, Europe, Latin America, the CIS, the Middle East, Africa and Asia, drawing on world-class facilities, innovation-driven R&D, a strong IP portfolio, commitment to quality and an efficient supply chain; the company has launched first-in-the-world generics for 16 state-of-the-art medicines at affordable prices, filed 300 patents, more than 500 DMFs/CEPs, more than 2,000 formulation dossiers and more than 40 ANDAs, with annual production capacity exceeding 4 billion units.

No comments available.
Leave your rating & comment